Precision oncology just gained a powerful new predictive tool for one of medicine's most challenging scenarios: treating locally advanced rectal cancer that lacks the genetic markers traditionally associated with immunotherapy success. This breakthrough could transform treatment decisions for thousands of patients annually who previously had limited therapeutic options beyond conventional chemoradiation.
The SILAR trial demonstrated that combining PD-1 inhibitor sintilimab with standard chemoradiation achieved pathologic complete response in 30 of 46 patients with proficient mismatch repair rectal cancer—a 65.2% success rate that far exceeds historical benchmarks. Crucially, the Immunoscore biomarker proved highly predictive: patients with high immune infiltration achieved 85.7% complete response versus 61.5% in the intermediate group. The treatment protocol involved six cycles of modified FOLFOX6 chemotherapy with concurrent radiation therapy, followed by surgical resection.
This finding addresses a critical gap in rectal cancer care, where mismatch repair proficient tumors comprise roughly 95% of cases yet historically show poor immunotherapy responsiveness. The Immunoscore—which quantifies immune cell infiltration patterns—emerges as a practical biomarker that could guide treatment selection without requiring complex genetic testing. The safety profile remained manageable, with leukopenia as the primary concern and only 15% experiencing grade 3 adverse events. While single-arm phase II trials require validation, these results suggest immunotherapy combinations may benefit a much broader rectal cancer population than previously recognized, potentially sparing many patients from more aggressive surgical approaches while improving cure rates.